Clinical Trials Directory

Trials / Unknown

UnknownNCT02392520

Luteal Antagonist Versus Conventional Treatment in Women With Severe Early Ovarian Hyperstimulation Syndrome (OHSS)

GnRH Antagonist in the Luteal Phase Compared to Conventional Treatment in Women With Severe Early Ovarian Hyperstimulation Syndrome (OHSS) in Whom All Embryos Are Cryopreserved

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
Eugonia · Academic / Other
Sex
Female
Age
18 Years – 49 Years
Healthy volunteers
Accepted

Summary

The study aims to compare the novel method of GnRH antagonist administration in the luteal phase versus conventional treatment in IVF patients who develop severe early ovarian hyperstimulation syndrome and have all their embryos cryopreserved.

Detailed description

GnRH antagonist administration in the luteal phase has been proposed as a strategy for the treatment of established severe early OHSS, causing rapid regression of the syndrome on an outpatient basis. The approach has been described as tertiary OHSS prevention, thereby complementing the primary prevention (GnRH antagonist protocol) and secondary prevention (GnRH agonist trigger) that constitute the OHSS-free clinic concept. No randomized controlled trials (RCT) exist to date comparing luteal GnRH antagonist administration versus conventional treatment. The aim of the present study is to compare the novel method of GnRH antagonist administration in the luteal phase versus conventional treatment with primary outcome time to severe OHSS regression, in IVF patients who develop severe early OHSS and have all their embryos cryopreserved.

Conditions

Interventions

TypeNameDescription
DRUGcetrorelix (cetrotide)0.25 mg GnRH antagonist cetrorelix will be administered once daily for 4 days, starting on the day of severe early OHSS diagnosis
DRUGPlacebointravenous albumin administration, paracentesis of ascitic fluid, correction of electrolyte imbalance and intravascular volume

Timeline

Start date
2015-05-01
Primary completion
2016-03-01
Completion
2016-12-01
First posted
2015-03-19
Last updated
2015-03-19

Locations

1 site across 1 country: Greece

Source: ClinicalTrials.gov record NCT02392520. Inclusion in this directory is not an endorsement.